Möchten Sie immer auf dem neuesten Stand bleiben?

Castle announced new data that confirm that the i31-SLNB accurately predicts SLN positivity and identifies low-risk patients who may safely forgo SLNB.

Castle will share new data evaluating DecisionDx-Melanoma’s i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity at SSO 2026.

Castle Biosciences announced the publication of an independent expert consensus paper endorsing the Company’s DecisionDx-Melanoma test.

Castle will present new data showing the clinical value of DecisionDx-Melanoma in improving sentinel lymph node biopsy decision making at Dermato-Onco2025.

Castle is presenting data on DecisionDx®-Melanoma and its pipeline atopic dermatitis (AD) test at the 25th Annual Fall Clinical Dermatology Conference.

Castle announced that its DecisionDx®-Melanoma test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).

Castle will present new data aimed at enhancing the clinical management of patients with cutaneous melanoma and uveal melanoma at ASCO 2025.

Castle continues its ongoing patient advocacy partnerships and highlights cancer journey to drive education and awareness for Skin Cancer Awareness Month

Castle announced the publication of a new study demonstrating DecisionDx-Melanoma outperforms AJCC staging and the CP-GEP test.

Castle announces its achievement of surpassing a significant milestone of 200,000 DecisionDx-Melanoma clinical test orders.